Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have developed the largest collection of sarcoma patient-derived organoids to date that can help improve the understanding of the disease and better identify therapies that are most likely to work for each individual patient.
FDA approved Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first-line treatment option for adult patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant.
FDA approved Tagrisso (osimertinib) in the U.S. for treatment of adult patients with unresectable, stage 3 epidermal growth factor receptor-mutated non-small cell lung cancer whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy.
The European Commission approved Vyloy (zolbetuximab) in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2-negative gastric or gastroesophageal junction adenocarcinoma whose tumors are claudin 18.2 positive.
The European Medicines Agency’s Committee for Medicinal Products for Human Use adopted positive opinions recommending approval of Keytruda (pembrolizumab), an anti-PD-1 therapy, for two indications in gynecologic cancers.
Bayer announced the submission of a supplemental new drug application to FDA for the oral androgen receptor inhibitor Nubeqa (darolutamide) in combination with androgen deprivation therapy for the treatment of patients with metastatic hormone-sensitive prostate cancer.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
The National Academy of Medicine recognized the value of correlative science in publicly funded clinical trials in 2010, recommending “the incorporation of innovative science into cancer clinical trials through the support and use of biorepositories.”
Artificial intelligence is starting to transform life sciences by accelerating drug discovery and development, optimizing clinical trials, and creating personalized treatments for cancer patients, speakers said at the Sept. 18 unveiling of the American Association for Cancer Research 2024 Cancer Progress Report.
The 2024 Albert Lasker Basic Medical Research Award went to Zhijian “James” Chen. The Lasker~DeBakey Clinical Medical Research Award went to Joel Habener, Lotte Bjerre Knudsen, and Svetlana Mojsov. The Lasker~Bloomberg Public Service Award went to Quarraisha Abdool Karim and Salim S. Abdool Karim.
